Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.64 |
| ▸ | SRC | P12931 | 4/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.64 |
| ▸ | PRKCG | P05129 | 3/20 | 0.64 |
| ▸ | PRKCB | P05771 | 3/20 | 0.64 |
| ▸ | PRKCA | P17252 | 3/20 | 0.64 |
| ▸ | PRKCH | P24723 | 3/20 | 0.64 |
| ▸ | PRKCI | P41743 | 3/20 | 0.64 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.64 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.64 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.64 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.64 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | CASP3 | P42574 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11878949 | 0.86 | KDM4E (0.53) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL3259553 | 0.85 | KDM4E (0.64) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL9566607 | 0.84 | KDM4E (0.51) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL9566625 | 0.84 | KDM4E (0.51) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL9657357 | 0.84 | EGFR (0.64) | EGFRSRCPRKD3PRKCGPRKCB | |
| Hydrochloric Acid SCHEMBL5138495 | 0.84 | KDM4E (0.62) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL17685237 | 0.81 | EGFR (0.64) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL5821140 | 0.81 | EGFR (0.64) | EGFRSRCMAPTMEN1KMT2A | |
| Cgp-53353 SCHEMBL230492 | 0.78 | EGFR (1.00) | EGFRSRCPRKD3PRKCGPRKCB | |
| Cgp-53353 SCHEMBL29766901 | 0.78 | EGFR (1.00) | EGFRSRCPRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114514019-A | Method for producing pharmaceutical preparations containing crystalline and amorphous fractions of active substances | 拜耳股份有限公司 | 2022-05-17 | — | — | CN | claimed |
| WO-2005037259-A2 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF NEOPLASIA COMPRISING A COX-2 INHIBITOR IN COMBINATION WITH AN EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONIST | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| US-20040127470-A1 | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | US | claimed |
| US-20030086924-A1 | Treatment with anti-ErbB2 antibodies | GENENTECH, INC. | 2003-05-08 | — | — | US | claimed |
| CN-1102643-A | Substituted derivatives of diaminophthalimide | CIBA GEIGY AG (CH) | 1995-05-17 | — | — | CN | claimed |
| CN-1067052-A | The diaminophthalimides and the analogue thereof that replace | CIBA GEIGY AG (CH) | 1992-12-16 | — | — | CN | claimed |
| CN-111936487-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-07-09 | — | — | CN | disclosed |
| US-12030946-B2 | Therapeutic and diagnostic methods for cancer | HOFFMANN-LA ROCHE INC. (US) | 2024-07-09 | — | — | US | disclosed |
| CN-118302411-A | Therapeutic indazole compounds and methods of use thereof for the treatment of cancer | 基因泰克公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-112312909-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118284686-A | Systems and methods for cell-based immunotherapy | 杭州启函生物科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207398-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | GENENTECH INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-6127374-A | AN ENZYME INHIBITOR FOR TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS, ENDOMETRIOSIS AND PSORIASIS | WARNER-LAMBERT COMPANY (US) | 2000-10-03 | — | — | US | disclosed |
| WO-2000010588-A9 | EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS FOR TREATING HYPERSECRETION OF MUCUS IN THE LUNGS | UNIV CALIFORNIA (US) | 2000-08-10 | — | — | WO | disclosed |
| WO-1999006396-A1 | IRREVERSIBLE BICYCLIC INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006378-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-02-11 | — | — | WO | disclosed |
| CN-1128495-A | Pharmaceutical formulations of poorly soluble active agents | SANDOZ LTD (CH) | 1996-08-07 | — | — | CN | disclosed |
| CN-1102643-A | Substituted derivatives of diaminophthalimide | CIBA GEIGY AG (CH) | 1995-05-17 | — | — | CN | disclosed |
| CN-1067052-A | The diaminophthalimides and the analogue thereof that replace | CIBA GEIGY AG (CH) | 1992-12-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, NQO1, PCSK9 | EGFR 1383/4885SRC 1392/4885PRKD3 1926/4885 |
| US-20040127470-A1 | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist | EGFR, PTGFR, ERBB2 | EGFR 1/4885SRC 351/4885PRKD3 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.